1254160-17-2

Basic information

• Product Name: sodium ((2R,3S,4R,5R)-5-(2-chloro-6-(cyclohexylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl sulfate
• Synonyms: sodium ((2R,3S,4R,5R)-5-(2-chloro-6-(cyclohexylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl sulfate
• CAS NO: 1254160-17-2
• Molecular Weight: 485.881
• Mol File: 1254160-17-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: sodium ((2R,3S,4R,5R)-5-(2-chloro-6-(cyclohexylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl sulfate(CAS DataBase Reference)
• NIST Chemistry Reference: sodium ((2R,3S,4R,5R)-5-(2-chloro-6-(cyclohexylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl sulfate(1254160-17-2)
• EPA Substance Registry System: sodium ((2R,3S,4R,5R)-5-(2-chloro-6-(cyclohexylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl sulfate(1254160-17-2)

Safety Data

• Hazardous Substances Data: 1254160-17-2(Hazardous Substances Data)

Upstream product

• 1338586-49-4 2-chloro-2',3'-isopropylidene-N⁶-cyclohexyladenosine 
• 38583-85-6 2-chloro-N⁶-cyclohexyladenosine 
• 13276-52-3 2,6-dichloropurine riboside 
• 108-91-8 cyclohexylamine 

Relevant articles and documents

METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION

The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.

COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE

The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan? and Compound A.